![]() However, current methods of evidence collection-such as clinical trials-do not account for these data elements, nor time horizons. As discussed in the previous 2 sections of this supplement, 1,2 the burden of Alzheimer’s escalates over the course of the disease and extends beyond direct medical costs, affecting caregivers, long-term care systems, economies, and society as a whole. There is a pressing need for payers, value assessors, and the broader Alzheimer’s community to integrate real-world evidence into long-term value assessments. The Need for Long-Term Value Demonstration in Alzheimer’s Disease Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Tufts University School of Medicine, Boston, MA, USA ![]() ![]() Paola Barbarino, MA, Chief Executive Officer, Alzheimer’s Disease International, London, England, UK Anders Gustavsson, PhD, MSc, Partner, Quantify Research Affiliate, Karolinska Institutet, Stockholm, Sweden Peter J. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |